Barrington Research Reaffirms “Outperform” Rating for Bioventus (NASDAQ:BVS)

Bioventus (NASDAQ:BVS)‘s stock had its “outperform” rating restated by investment analysts at Barrington Research in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $14.00 price target on the stock. Barrington Research’s price target indicates a potential upside of 47.52% from the stock’s previous close.

A number of other brokerages have also recently commented on BVS. Cantor Fitzgerald raised shares of Bioventus to a “strong-buy” rating in a report on Wednesday, March 4th. Craig Hallum upped their target price on shares of Bioventus from $15.00 to $16.00 and gave the company a “buy” rating in a report on Friday, March 6th. Finally, CJS Securities began coverage on shares of Bioventus in a report on Friday, March 27th. They issued a “market outperform” rating and a $14.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, Bioventus currently has an average rating of “Buy” and an average price target of $14.00.

Bioventus Price Performance

Shares of BVS opened at $9.49 on Friday. Bioventus has a 1-year low of $5.81 and a 1-year high of $11.25. The stock has a market cap of $792.79 million, a PE ratio of 23.15, a price-to-earnings-growth ratio of 1.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.69 and a quick ratio of 1.13. The firm has a fifty day moving average price of $9.65 and a 200 day moving average price of $8.47.

Bioventus (NASDAQ:BVS) last announced its quarterly earnings results on Wednesday, May 6th. The company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.06. Bioventus had a net margin of 4.94% and a return on equity of 29.97%. The firm had revenue of $132.09 million during the quarter. Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. As a group, sell-side analysts anticipate that Bioventus will post 0.79 EPS for the current year.

Insider Activity

In other news, Director Michelle Mcmurry-Heath sold 12,000 shares of the business’s stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $8.79, for a total transaction of $105,480.00. Following the transaction, the director directly owned 44,997 shares in the company, valued at $395,523.63. The trade was a 21.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 33.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd increased its stake in shares of Bioventus by 17,156.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 5,522 shares of the company’s stock worth $41,000 after acquiring an additional 5,490 shares during the period. Covestor Ltd grew its position in Bioventus by 28.0% during the third quarter. Covestor Ltd now owns 9,951 shares of the company’s stock worth $67,000 after buying an additional 2,176 shares during the period. Olympiad Research LP acquired a new position in Bioventus during the third quarter worth about $74,000. Prelude Capital Management LLC acquired a new position in Bioventus during the third quarter worth about $74,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in Bioventus during the third quarter worth about $78,000. 62.94% of the stock is currently owned by institutional investors and hedge funds.

About Bioventus

Bioventus, headquartered in Durham, North Carolina, is a global medical device company specializing in orthobiologic solutions aimed at accelerating healing and improving patient outcomes in musculoskeletal conditions. The company develops and commercializes a portfolio of non‐surgical therapies designed to address bone healing, osteoarthritis pain management and soft tissue repair. Its flagship EXOGEN® Ultrasound Bone Healing System utilizes low‐intensity pulsed ultrasound technology to stimulate bone growth and has been widely used in the management of delayed fractures and nonunions.